Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Panobinostat (Primary) ; Rituximab (Primary) ; Dexamethasone; Filgrastim; Glutamine; Palifermin; Pyridoxine; Pyridoxine
Indications Diffuse large B cell lymphoma; Hodgkin's disease; T-cell lymphoma
Focus Therapeutic Use

20 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
21 Mar 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Jun 2021.
21 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com